Skip to main content
SpringerLink
Log in

Interleukin-1 Mediated Autoinflammation from Heart Disease to Cancer

  • Chapter
  • First Online:
Textbook of Autoinflammation

Abstract

Interleukin-(IL)-1α and IL-1β are highly active proinflammatory cytokines which lower pain thresholds and damage tissues. Monotherapy blocking IL-1 in hereditary autoinflammatory syndromes results in a rapid and sustained reduction in disease severity. But blocking IL-1 activity is also effective in treating common conditions such as gout and post-myocardial infarction heart failure. Targeting IL-1 in a broad spectrum of new indications is ongoing. There are several trials of IL-1 inhibition in cancer. Initially believed to be contraindicated, targeting IL-1 in cancer has expanded greatly. Anti-IL-1α has been used to treat patients with metastatic lung and colorectal cancers, advanced pancreatic cancer, human epidermal growth factor receptor 2 (HER2) negative breast cancer and with smoldering myeloma. A placebo controlled randomized trial of canakinumab in over 10,000 subjects revealed a marked decrease in the incidence and survival of patients with lung cancer. In each of these cancers, a role for IL-1 mediated autoinflammation is a fundamental mechanism of action.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

3-MCA:

3-methylcholanthrene

AOSD:

Adult-onset Still disease

BMI:

Body mass index

CANTOS:

Canakinumab Anti-inflammatory Thrombosis Outcomes Study

CAPS:

Cryopyrin-associated periodic syndrome

CRP:

C-reactive protein

CSF:

Cerebrospinal fluid

CTLA-4:

Cytotoxic T-lymphocyte-associated protein 4

FMF:

Familial Mediterranean fever

HER2:

Human epidermal growth factor receptor 2

IL:

Interleukin

IL-1R1:

IL-1 receptor 1

IL-1Ra:

IL-1 receptor antagonist

LBM:

Lean body mass

MABp1:

Monoclonal antibody p1

MCD-1:

Macrophage-derived chemoattractant-1

MDSC:

Myeloid-derived suppressor cells

NIHSS:

National Institutes of Health stroke scale

NK:

Natural killer

NLRP3:

Nucleotide-binding domain and leucine-rich repeat pyrin containing 3

NOMID:

Neonatal-onset multisystem inflammatory disease

PD-1:

Programmed cell death protein 1

STEMI:

ST-elevated myocardial infarction

TAM:

Tumor-associated macrophages

TNF:

Tumor necrosis factor

TRAPS:

TNF receptor-associated periodic syndrome

WT:

Wild type

References

  1. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 2007;56(9):3138–48.

    Article  CAS  PubMed  Google Scholar 

  3. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006;355(6):581–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Netea MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Harrison SR, McGonagle D, Nizam S, et al. Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology. JCI Insight. 2016;1(6):e86336.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.

    Article  CAS  PubMed  Google Scholar 

  8. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009;61(3):344–52.

    Article  CAS  PubMed  Google Scholar 

  9. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol. 2005;32(7):1317–23.

    CAS  PubMed  Google Scholar 

  10. Bacconnier L, Jorgensen C, Fabre S. Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis. 2009;68(6):1078–9.

    Article  CAS  PubMed  Google Scholar 

  11. Cohen SB, Proudman S, Kivitz AJ, et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL 1R1) in patients with osteoarthritis of the knee. Arthritis Res Ther. 2011;13(4):R125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Abbate A, Kontos MC, Grizzard JD, et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra remodeling trial [VCU-ART] pilot study). Am J Cardiol. 2010;105(10):1371–7.e1.

    Article  CAS  PubMed  Google Scholar 

  13. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra remodeling trial (2) (VCU-ART2) pilot study]. Am J Cardiol. 2013;111(10):1394–400.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Toldo S, Mezzaroma E, Van Tassell BW, et al. Interleukin-1beta blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp Physiol. 2013;98(3):734–45.

    Article  CAS  PubMed  Google Scholar 

  15. Morton AC, Rothman AM, Greenwood JP, et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J. 2015;36(6):377–84.

    Article  CAS  PubMed  Google Scholar 

  16. Cain BS, Meldrum DR, Dinarello CA, et al. Tumor necrosis factor-a and interleukin-1b synergistically depress human myocardial function. Crit Care Med. 1999;27(7):1309–18.

    Article  CAS  PubMed  Google Scholar 

  17. Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7(3):e33438.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113(2):321–7.

    Article  PubMed  Google Scholar 

  19. Van Tassell BW, Abouzaki NA, Oddi Erdle C, et al. Interleukin-1 blockade in acute decompensated heart failure: a randomized, double-blinded, placebo-controlled pilot study. J Cardiovasc Pharmacol. 2016;67(6):544–51.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Van Tassell BW, Buckley LF, Carbone S, et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the diastolic heart failure Anakinra response trial 2 (D-HART2). Clin Cardiol. 2017;40(9):626–32.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation. 2008;117(20):2662–9.

    Article  CAS  PubMed  Google Scholar 

  22. Raffeiner B, Botsios C, Dinarello CA, Ometto F, Punzi L, Ramonda R. Adult-onset Still’s disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine. 2011;78(1):100–1.

    Article  CAS  PubMed  Google Scholar 

  23. Choi AD, Moles V, Fuisz A, Weissman G. Cardiac magnetic resonance in myocarditis from adult onset Still’s disease successfully treated with anakinra. Int J Cardiol. 2014;172(1):e225–7.

    Article  PubMed  Google Scholar 

  24. Cavalli G, Foppoli M, Cabrini L, Dinarello CA, Tresoldi M, Dagna L. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front Immunol. 2017;8:131.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Cavalli G, Pappalardo F, Mangieri A, Dinarello CA, Dagna L, Tresoldi M. Treating life-threatening myocarditis by blocking interleukin-1. Crit Care Med. 2016;44(8):e751–4.

    Article  CAS  PubMed  Google Scholar 

  26. Waghmare S, Valecka B, Cairns AP. A severe case of adult onset Stills disease with myopericarditis, resistant to treatment with tocilizumab but responsive to anakinra. Ulster Med J. 2015;84(2):130–2.

    PubMed  Google Scholar 

  27. Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology. 2010;74(16):1267–70.

    Article  CAS  PubMed  Google Scholar 

  28. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360(23):2416–25.

    Article  CAS  PubMed  Google Scholar 

  29. Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis. 2011;70(12):2095–102.

    Article  CAS  PubMed  Google Scholar 

  30. Goldbach-Mansky R. Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr Rheumatol Rep. 2011;13(2):123–31.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 2011;62(1):258–67.

    Article  Google Scholar 

  32. Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr. 2011;157(2):310–5.e1.

    Article  Google Scholar 

  33. Singh N, Hopkins SJ, Hulme S, et al. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J Neuroinflammation. 2014;11:1.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Clark SR, McMahon CJ, Gueorguieva I, et al. Interleukin-1 receptor antagonist penetrates human brain at experimentally therapeutic concentrations. J Cereb Blood Flow Metab. 2008;28(2):387–94.

    Article  CAS  PubMed  Google Scholar 

  35. Galea J, Ogungbenro K, Hulme S, et al. Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab. 2011;31(2):439–47.

    Article  CAS  PubMed  Google Scholar 

  36. Ogungbenro K, Hulme S, Rothwell N, Hopkins S, Tyrrell P, Galea J. Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist. J Pharmacokinet Pharmacodyn. 2016;43(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  37. Emsley HC, Smith CJ, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry. 2005;76(10):1366–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Helmy A, Guilfoyle MR, Carpenter KL, Pickard JD, Menon DK, Hutchinson PJ. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J Cereb Blood Flow Metab. 2014;34(5):845–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun. 2011;25(7):1281–9.

    Article  CAS  PubMed  Google Scholar 

  40. Heida JG, Moshe SL, Pittman QJ. The role of interleukin-1beta in febrile seizures. Brain and Development. 2009;31(5):388–93.

    Article  PubMed  Google Scholar 

  41. Uludag IF, Bilgin S, Zorlu Y, Tuna G, Kirkali G. Interleukin-6, interleukin-1 beta and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure. 2013;22(6):457–61.

    Article  PubMed  Google Scholar 

  42. Uludag IF, Duksal T, Tiftikcioglu BI, Zorlu Y, Ozkaya F, Kirkali G. IL-1beta, IL-6 and IL1Ra levels in temporal lobe epilepsy. Seizure. 2015;26:22–5.

    Article  PubMed  Google Scholar 

  43. Chou IC, Lin WD, Wang CH, Tsai CH, Li TC, Tsai FJ. Interleukin (IL)-1beta, IL-1 receptor antagonist, IL-6, IL-8, IL-10, and tumor necrosis factor alpha gene polymorphisms in patients with febrile seizures. J Clin Lab Anal. 2010;24(3):154–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Haspolat S, Baysal Y, Duman O, Coskun M, Tosun O, Yegin O. Interleukin-1alpha, interleukin-1beta, and interleukin-1Ra polymorphisms in febrile seizures. J Child Neurol. 2005;20(7):565–8.

    Article  PubMed  Google Scholar 

  45. Kanemoto K, Kawasaki J, Miyamoto T, Obayashi H, Nishimura M. Interleukin (IL)1beta, IL-1alpha, and IL-1 receptor antagonist gene polymorphisms in patients with temporal lobe epilepsy. Ann Neurol. 2000;47(5):571–4.

    Article  CAS  PubMed  Google Scholar 

  46. Nakayama J, Arinami T. Molecular genetics of febrile seizures. Epilepsy Res. 2006;70(Suppl 1):S190–8.

    Article  CAS  PubMed  Google Scholar 

  47. Serdaroglu G, Alpman A, Tosun A, et al. Febrile seizures: interleukin 1beta and interleukin-1 receptor antagonist polymorphisms. Pediatr Neurol. 2009;40(2):113–6.

    Article  PubMed  Google Scholar 

  48. Krelin Y, Voronov E, Dotan S, et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 2007;67(3):1062–71.

    Article  CAS  PubMed  Google Scholar 

  49. Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833–42.

    Article  CAS  PubMed  Google Scholar 

  50. Lust JA, Lacy MQ, Zeldenrust SR, et al. Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. Am J Hematol. 2016;91(6):571–4.

    Article  CAS  PubMed  Google Scholar 

  51. Dinarello CA. Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 2010;29(2):317–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med. 2006;4:48.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Voronov E, Shouval DS, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A. 2003;100(5):2645–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Carmi Y, Voronov E, Dotan S, et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol. 2009;183(7):4705–14.

    Article  CAS  PubMed  Google Scholar 

  55. Carmi Y, Dotan S, Rider P, et al. The role of IL-1beta in the early tumor cell-induced angiogenic response. J Immunol. 2013;190(7):3500–9.

    Article  CAS  PubMed  Google Scholar 

  56. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am. 1999;13(6):1117–25.

    Article  CAS  PubMed  Google Scholar 

  57. Pusztai L, Mendoza TR, Reuben JM, et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine. 2004;25(3):94–102.

    Article  CAS  PubMed  Google Scholar 

  58. Hong DS, Janku F, Naing A, et al. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Investig New Drugs. 2015;33(3):621–31.

    Article  CAS  Google Scholar 

  59. Hickish T, Andre T, Wyrwicz L, et al. MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2017;18(2):192–201.

    Article  CAS  PubMed  Google Scholar 

  60. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation. 1999;99(16):2079–84.

    Article  CAS  PubMed  Google Scholar 

  61. Hong DS, Hui D, Bruera E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15(6):656–66.

    Article  CAS  PubMed  Google Scholar 

  62. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc. 2009;84(2):114–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Becerra C, Paulson AS, Cavaness K, Hoof PD, Celinski S. Gemcitabine, nab-paclitaxel, cisplatin, and anakinra (AGAP) treatment in patients with non-metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol (suppl=e). 2018 (in press).

    Google Scholar 

  64. Cheng LL, Ma MJ, Becerra L, et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 1997;94(12):6408–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Isambert N, Hervieu A, Hennequin A, et al. Fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): an investigator-initiated, open-label, single-arm, multicenter, phase 2 study. ASCO. 2018 (in press).

    Google Scholar 

  66. Wu T-C, Xu K, Martinek J, et al. IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer. Cancer Res. 2018 (in press).

    Google Scholar 

  67. Xiong Y, Donovan KA, Kline MP, et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interf Cytokine Res. 2006;26(2):83–95.

    Article  CAS  Google Scholar 

  68. O’Shaughnessy C, Young RR, Levin MK, et al. Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer. J Clin Oncol. 2016;34(Suppl):e14565.

    Article  Google Scholar 

  69. Wang Y, Wang Y, Li L. Note of clarification regarding data about the association between the interleukin-1beta -31T>C polymorphism and breast cancer risk. Breast Cancer Res Treat. 2016;155(3):415–7.

    Article  PubMed  Google Scholar 

  70. Kim B, Lee Y, Kim E, et al. The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front Immunol. 2013;4:391.

    PubMed  PubMed Central  Google Scholar 

  71. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33–40.

    Article  CAS  PubMed  Google Scholar 

  72. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med. 1983;308(10):553–8.

    Article  CAS  PubMed  Google Scholar 

  73. Smith JW 2nd, Longo DL, Alvord WG, et al. The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N Engl J Med. 1993;328(11):756–61.

    Article  PubMed  Google Scholar 

  74. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood. 1993;81(10):2492–5.

    CAS  PubMed  Google Scholar 

  75. Smith CJ, Emsley HC, Udeh CT, et al. Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine. 2012;58(3):384–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by NIH Grant AI-15614, the Colorado Cancer Center and National Cancer Institute Grant P30CA046934. The author thanks Dr. Giulio Cavalli for his help with the sections on osteoarthritis and heart disease.

Author information

Authors and Affiliations

  1. Department of Medicine, Colorado Cancer Center, University of Colorado, Aurora, CO, USA

    Charles A. Dinarello

  2. Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

    Charles A. Dinarello

Authors
  1. Charles A. Dinarello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles A. Dinarello .

Editor information

Editors and Affiliations

  1. Pediatric Rheumatology Unit, Shaare Zedek Medical Center and Hebrew University, Jerusalem, Israel

    Philip J. Hashkes

  2. Department Paediatrics, Division of Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada

    Ronald M. Laxer

  3. Department of Internal Medicine, Radboudumc Expertisecenter for Immunodeficiency and Autoinflammation, Radboud University Medical Center, Nijmegen, The Netherlands

    Anna Simon

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Dinarello, C.A. (2019). Interleukin-1 Mediated Autoinflammation from Heart Disease to Cancer. In: Hashkes, P., Laxer, R., Simon, A. (eds) Textbook of Autoinflammation. Springer, Cham. https://doi.org/10.1007/978-3-319-98605-0_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98605-0_39

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98604-3

  • Online ISBN: 978-3-319-98605-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation